ArticlePloS one2026
A multi-product, multi-period vaccine supply chain network planning with injection centers and storage conditions.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study develops a mixed-integer linear programming model for a multi-product, multi-period vaccine supply chain network that incorporates injection centers and heterogeneous storage conditions, including cold and ultra-cold refrigeration. The model captures key operational decisions such as distribution center location, vaccine allocation, and storage configuration under capacity and demand constraints, while ensuring no shortage at injection centers. To efficiently solve large-scale instances, a tailored genetic algorithm (GA) is proposed. The main achievements of this research are as follows. First, the proposed model provides an integrated framework that simultaneously considers multi-vaccine characteristics and storage requirements within a three-tier supply chain. Second, computational experiments demonstrate that the GA achieves high-quality solutions with very small optimality gaps compared to exact solutions obtained by GAMS for small and medium-sized problems. Third, the results show that while exact methods become computationally inefficient or infeasible for large-scale instances, the GA remains robust and capable of producing near-optimal solutions within reasonable computational time. Finally, sensitivity analysis confirms the consistency and validity of the model, showing that total cost increases logically with demand and cost parameters. These findings highlight the effectiveness and scalability of the proposed approach and demonstrate its applicability as a decision-support tool for policymakers and healthcare planners in managing complex vaccine distribution systems, particularly during large-scale public health emergencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.